Evidence map›Paper›PMID 26170283›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Functional expression of sodium-glucose transporters in cancer.

Claudio Scafoglio, Bruce A Hirayama, Vladimir Kepe, Jie Liu, Chiara Ghezzi, Nagichettiar Satyamurthy, Neda A Moatamed, Jiaoti Huang, Hermann Koepsell, Jorge R Barrio and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 195 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
195citing papers in PubMed, 3 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

195 citing papers in PubMed, 3 syntheses or guidelines pooled it, 321 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

135 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Claudio ScafoglioDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-6948;
Bruce A HirayamaDepartment of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1751;
Vladimir KepeDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-6948;
Jie LiuDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-6948;
Chiara GhezziDepartment of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1751;
Nagichettiar SatyamurthyDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-6948;
Neda A MoatamedDepartment of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095;
Jiaoti HuangDepartment of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095;
Hermann KoepsellInstitute for Anatomy and Cell Biology, University of Würzburg, 97070 Würzburg, Germany.
Jorge R BarrioDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-6948; jbarrio@mednet.ucla.edu ewright@mednet.ucla.edu.
Ernest M WrightDepartment of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1751; jbarrio@mednet.ucla.edu ewright@mednet.ucla.edu.
University of California, Los Angeles · USUniversity of Würzburg · DE

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
UCLA Scholars in Oncologic Molecular lmaging (SOMI)R25CA098010 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PHELPS, MICHAEL E · 2003 to 2013
$5.0M
MOLECULAR MECHANISMS OF INTESTINAL TRANSPORTR01DK019567 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WRIGHT, ERNEST M · 1986 to 2013
$4.3M
Role of SGLTs in Glucose Homeostasis and Tissue MetabolismR01DK077133 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WRIGHT, ERNEST M · 2008 to 2011
$1.3M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS R25 CA098010NIDDK NIH HHS DK077133NIDDK NIH HHS DK19567NIDDK NIH HHS P30 DK041301NIDDK NIH HHS R01 DK019567NIDDK NIH HHS R01 DK077133
6 · The paper itself

Abstract

Glucose is a major metabolic substrate required for cancer cell survival and growth. It is mainly imported into cells by facilitated glucose transporters (GLUTs). Here we demonstrate the importance of another glucose import system, the sodium-dependent glucose transporters (SGLTs), in pancreatic and prostate adenocarcinomas, and investigate their role in cancer cell survival. Three experimental approaches were used: (i) immunohistochemical mapping of SGLT1 and SGLT2 distribution in tumors; (ii) measurement of glucose uptake in fresh isolated tumors using an SGLT-specific radioactive glucose analog, α-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG), which is not transported by GLUTs; and (iii) measurement of in vivo SGLT activity in mouse models of pancreatic and prostate cancer using Me4FDG-PET imaging. We found that SGLT2 is functionally expressed in pancreatic and prostate adenocarcinomas, and provide evidence that SGLT2 inhibitors block glucose uptake and reduce tumor growth and survival in a xenograft model of pancreatic cancer. We suggest that Me4FDG-PET imaging may be used to diagnose and stage pancreatic and prostate cancers, and that SGLT2 inhibitors, currently in use for treating diabetes, may be useful for cancer therapy.

Indexed as

AdenocarcinomaAnimalsBiological TransportFemaleFluorine RadioisotopesGene Expression ProfilingGene Expression Regulation, NeoplasticGlucose Transport Proteins, FacilitativeGlucosidesHumansImmunohistochemistryKidneyMaleMiceNecrosisNeoplasm TransplantationFluorine RadioisotopesGlucose Transport Proteins, FacilitativeGlucosidesmethyl-4-fluoro-4-deoxyglucoseSLC5A2 protein, humanSlc5a2 protein, mouseSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorspancreatic cancerprostate cancerSGLT2SGLT2-inhibitors

Identifiers

PMID26170283
PMCPMC4522748
OpenAlexW1883655199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.